# AirJoule Technologies Corp.: financial statements, quarterly

AIRJ · Nasdaq · CIK 1855474 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/airj.md) · [Financials](/companies/airj/financials.md) · [Filings](/companies/airj/filings.md) · [Insiders](/companies/airj/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/airj/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | [0.8](/filings/0000950170-25-070295.md) | [1.1](/filings/0000950170-25-108487.md) | not reported | not reported | [0.4](/filings/0000950170-25-070295.md) | [0.4](/filings/0000950170-25-108487.md) | not reported | not reported | not reported | not reported |
| Operating income | $m | [(4.6)](/filings/0001213900-24-097448.md) | [(3.0) d](/filings/0001013762-25-002263.md) | [(56.4)](/filings/0000950170-25-070295.md) | [(4.3)](/filings/0000950170-25-108487.md) | [(2.4)](/filings/0001193125-25-281648.md) | [(2.8) d](/filings/0001193125-26-133335.md) | [(3.2)](/filings/0001193125-26-225395.md) | [(4.2)](/filings/0001193125-26-350442.md) | [(3.0)](/filings/0001193125-25-281648.md) | [(3.2) d](/filings/0001193125-26-133335.md) | [(3.6)](/filings/0001193125-26-225395.md) | [(4.1)](/filings/0001193125-26-350442.md) |
| Income tax | $m | [0.3](/filings/0001213900-23-085330.md) | [0.3 d](/filings/0001213900-24-021392.md) | [85.7](/filings/0000950170-25-070295.md) | [(1.2)](/filings/0000950170-25-108487.md) | [(1.3)](/filings/0001193125-25-281648.md) | [(2.0) d](/filings/0001193125-26-133335.md) | [(1.6)](/filings/0001193125-26-225395.md) | [(1.6)](/filings/0001193125-26-350442.md) | [(2.4)](/filings/0001193125-25-281648.md) | [(12.7) d](/filings/0001193125-26-133335.md) | [(14.7)](/filings/0001193125-26-225395.md) | [(2.9)](/filings/0001193125-26-350442.md) |
| Net income | $m | [(4.5)](/filings/0001213900-24-097448.md) | [(3.0) d](/filings/0001013762-25-002263.md) | [182](/filings/0001193125-25-281648.md) | [13.4](/filings/0001193125-25-281648.md) | [35.0](/filings/0001193125-25-281648.md) | [(14.3) d](/filings/0001193125-26-133335.md) | [14.9](/filings/0001193125-26-350442.md) | [2.5](/filings/0001193125-26-350442.md) | [(4.0)](/filings/0001193125-25-281648.md) | [(22.4) d](/filings/0001193125-26-133335.md) | [(49.8)](/filings/0001193125-26-350442.md) | [(8.5)](/filings/0001193125-26-350442.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.3](/filings/0001213900-23-085330.md) | [0.1](/filings/0001213900-24-021392.md) | [27.4](/filings/0001213900-24-071999.md) | [10.0](/filings/0001213900-24-072000.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [0.4](/filings/0001213900-23-085330.md) | [0.5](/filings/0001013762-25-002263.md) | [27.9](/filings/0001213900-24-071999.md) | [36.0](/filings/0001213900-24-072000.md) | [33.6](/filings/0001213900-24-097448.md) | [31.5](/filings/0001193125-26-133335.md) | [24.4](/filings/0000950170-25-070295.md) | [32.0](/filings/0000950170-25-108487.md) | [27.9](/filings/0001193125-25-281648.md) | [23.8](/filings/0001193125-26-350442.md) | [32.8](/filings/0001193125-26-225395.md) | [43.2](/filings/0001193125-26-350442.md) |
| Total assets | $m | [113](/filings/0001213900-23-085330.md) | [0.6](/filings/0001013762-25-002263.md) | [372](/filings/0001213900-24-071999.md) | [379](/filings/0001213900-24-072000.md) | [374](/filings/0001213900-24-097448.md) | [370](/filings/0001193125-26-133335.md) | [366](/filings/0000950170-25-070295.md) | [376](/filings/0000950170-25-108487.md) | [373](/filings/0001193125-25-281648.md) | [341](/filings/0001193125-26-350442.md) | [296](/filings/0001193125-26-225395.md) | [307](/filings/0001193125-26-350442.md) |
| Current liabilities | $m | [8.3](/filings/0001213900-23-085330.md) | [6.4](/filings/0001013762-25-002263.md) | [11.7](/filings/0001213900-24-071999.md) | [3.5](/filings/0001213900-24-072000.md) | [4.5](/filings/0001213900-24-097448.md) | [4.0](/filings/0001193125-26-133335.md) | [1.7](/filings/0000950170-25-070295.md) | [2.5](/filings/0000950170-25-108487.md) | [2.0](/filings/0001193125-25-281648.md) | [2.3](/filings/0001193125-26-350442.md) | [1.4](/filings/0001193125-26-225395.md) | [2.2](/filings/0001193125-26-350442.md) |
| Total liabilities | $m | [14.3](/filings/0001213900-23-085330.md) | [6.5](/filings/0001013762-25-002263.md) | [173](/filings/0001213900-24-071999.md) | [149](/filings/0001213900-24-072000.md) | [109](/filings/0001213900-24-097448.md) | [118](/filings/0001193125-26-133335.md) | [95.4](/filings/0000950170-25-070295.md) | [87.5](/filings/0000950170-25-108487.md) | [86.4](/filings/0001193125-25-281648.md) | [72.7](/filings/0001193125-26-350442.md) | [55.2](/filings/0001193125-26-225395.md) | [58.2](/filings/0001193125-26-350442.md) |
| Shareholders' equity | $m | [(2.9)](/filings/0001213900-24-097448.md) | [(5.9)](/filings/0001193125-26-133335.md) | [198](/filings/0001193125-25-281648.md) | [230](/filings/0001193125-25-281648.md) | [266](/filings/0001193125-25-281648.md) | [252](/filings/0001193125-26-350442.md) | [270](/filings/0001193125-26-350442.md) | [289](/filings/0001193125-26-350442.md) | [286](/filings/0001193125-25-281648.md) | [268](/filings/0001193125-26-350442.md) | [241](/filings/0001193125-26-350442.md) | [249](/filings/0001193125-26-350442.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.2) d](/filings/0001213900-24-097448.md) | [(1.1) d](/filings/0001013762-25-002263.md) | [(6.4)](/filings/0000950170-25-070295.md) | [(11.2) d](/filings/0000950170-25-108487.md) | [(4.0) d](/filings/0001193125-25-281648.md) | [(2.7) d](/filings/0001193125-26-133335.md) | [0.1](/filings/0001193125-26-225395.md) | [(2.2) d](/filings/0001193125-26-350442.md) | [(1.9) d](/filings/0001193125-25-281648.md) | [(1.6) d](/filings/0001193125-26-133335.md) | [(2.3)](/filings/0001193125-26-225395.md) | [(1.4) d](/filings/0001193125-26-350442.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001213900-24-097448.md) | [0.0 d](/filings/0001013762-25-002263.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-281648.md) | [0.0 d](/filings/0001193125-26-133335.md) | [0.0](/filings/0001193125-26-225395.md) | [0.0 d](/filings/0001193125-26-350442.md) | [0.0 d](/filings/0001193125-25-281648.md) | [0.0 d](/filings/0001193125-26-133335.md) | [0.0](/filings/0001193125-26-225395.md) | [0.0 d](/filings/0001193125-26-350442.md) |
| Share repurchases | $m | [0.0 d](/filings/0001213900-23-085330.md) | [0.0 d](/filings/0001213900-24-021392.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

Shares outstanding: 73,347,394 at 2026-08-01, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-350442.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.